Crescent Biopharma vs Shattuck Labs
Crescent Biopharma is the larger business, with $10.8m of revenue in fiscal 2025 against $1.0m for Shattuck Labs (10.8 times as much). Crescent Biopharma grew faster (108340.0% against -82.5%). Crescent Biopharma kept more of each dollar of sales as profit: a net margin of -1419.6% against -4880.9%. Crescent Biopharma carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Crescent BiopharmaCBIO, 2025 | Shattuck LabsSTTK, 2025 |
|---|---|---|
| Revenue | $10.8m | $1.0m |
| Revenue growth | 108340.0% | -82.5% |
| Net income | −$154m | −$48.8m |
| Operating margin | -1407.5% | -5150.8% |
| Net margin | -1419.6% | -4880.9% |
| Return on equity | -127.5% | -60.3% |
| Free cash flow | −$72.5m | −$40.0m |
| Cash | $213m | $54.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 44 | 40 |
| Market value | $364m | $546m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 2 buys, 16 sales | 1 buys, 6 sales |